TY - JOUR
T1 - Estimated plasma osmolarity and risk of end-stage kidney disease in patients with IgA nephropathy
AU - Tanaka, Shigeru
AU - Nakano, Toshiaki
AU - Tokumoto, Masanori
AU - Masutani, Kosuke
AU - Tsuchimoto, Akihiro
AU - Ooboshi, Hiroaki
AU - Kitazono, Takanari
N1 - Funding Information:
This study was supported by Grants-in-Aid for Scientific Research (18K17405) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Acknowledgements
Publisher Copyright:
© 2020, Japanese Society of Nephrology.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Background: Several experimental studies have indicated that increased plasma osmolarity caused by recurrent dehydration is involved in kidney injury via a mechanism, mediated by vasopressin secretion and activation of the aldose reductase pathway. Epidemiologic evidence linking increased plasma osmolarity and the onset of end-stage kidney disease (ESKD), in patients with primary glomerulonephritis, is lacking. Methods: We retrospectively examined 663 patients with IgA nephropathy (IgAN) diagnosed by kidney biopsy and evaluated the association between estimated plasma osmolarity and ESKD prevalence, using a Cox proportional hazards model. Results: During follow-up (median 80.4 months; interquartile range 22.2–120.1), 73 patients developed ESKD. In a baseline survey, plasma osmolarity was correlated negatively with the mean value of the estimated glomerular filtration rate, but correlated positively with the mean value of urinary protein excretion, systolic blood pressure, and pathologic severity of extracapillary proliferation, in addition to tissue fibrosis and sclerosis. The incidence rate of ESKD increased linearly with increase in plasma osmolarity (P ' 0.05 for trend). In multivariate analyses, plasma osmolarity was an independent risk factor for ESKD (hazard ratio for each increment of 5 mOsm/kg in plasma osmolarity 1.56; 95% confidence interval 1.18–2.07) even after adjustment for potential confounders. Conclusions: Increased plasma osmolarity was associated significantly with an increased risk of ESKD in patients with IgAN. Maintenance of plasma osmolarity by appropriate control of the balance between salt and water may contribute to kidney protection.
AB - Background: Several experimental studies have indicated that increased plasma osmolarity caused by recurrent dehydration is involved in kidney injury via a mechanism, mediated by vasopressin secretion and activation of the aldose reductase pathway. Epidemiologic evidence linking increased plasma osmolarity and the onset of end-stage kidney disease (ESKD), in patients with primary glomerulonephritis, is lacking. Methods: We retrospectively examined 663 patients with IgA nephropathy (IgAN) diagnosed by kidney biopsy and evaluated the association between estimated plasma osmolarity and ESKD prevalence, using a Cox proportional hazards model. Results: During follow-up (median 80.4 months; interquartile range 22.2–120.1), 73 patients developed ESKD. In a baseline survey, plasma osmolarity was correlated negatively with the mean value of the estimated glomerular filtration rate, but correlated positively with the mean value of urinary protein excretion, systolic blood pressure, and pathologic severity of extracapillary proliferation, in addition to tissue fibrosis and sclerosis. The incidence rate of ESKD increased linearly with increase in plasma osmolarity (P ' 0.05 for trend). In multivariate analyses, plasma osmolarity was an independent risk factor for ESKD (hazard ratio for each increment of 5 mOsm/kg in plasma osmolarity 1.56; 95% confidence interval 1.18–2.07) even after adjustment for potential confounders. Conclusions: Increased plasma osmolarity was associated significantly with an increased risk of ESKD in patients with IgAN. Maintenance of plasma osmolarity by appropriate control of the balance between salt and water may contribute to kidney protection.
UR - http://www.scopus.com/inward/record.url?scp=85087039449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087039449&partnerID=8YFLogxK
U2 - 10.1007/s10157-020-01919-3
DO - 10.1007/s10157-020-01919-3
M3 - Article
C2 - 32594371
AN - SCOPUS:85087039449
SN - 1342-1751
VL - 24
SP - 910
EP - 918
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
IS - 10
ER -